In the US, it is competing in the METex14-positive NSCLC market with Novartis/Incyte's rival MET inhibitor Tabrecta (capmatinib). The EAMS opinion is based on results from the phase 2 VISION study ...

J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...

It is the first cMET inhibitor to reach the market in China, ahead of rival therapies such as Novartis/Incyte's Tabrecta (capmatinib) and Merck KGaA's Tepmetko (tepotinib), which have both been ...